LUCIANO ROSSETTI, MD
Osteopathic Medicine at Morris Park Ave, Bronx, NY
License number
New York 195425
Category
Osteopathic Medicine
Type
Internal Medicine
Address
Address
2
1300 Morris Park Ave, Bronx, NY 10461
4 Sherwood Ln, Bedford Hills, NY 10507
4 Sherwood Ln, Bedford Hills, NY 10507
Phone
(718) 430-2908
Personal information
See more information about LUCIANO ROSSETTI at radaris.comName
Address
Phone
4 Sherwood Ln, Bedford Hills, NY 10507
21 Tall Pines Ln, Mount Kisco, NY 10549
1775 York Ave, New York, NY 10128
Organization information
See more information about LUCIANO ROSSETTI at bizstanding.comLuciano Rossetti MD
1300 Morris Ave, Bronx, NY 10456
Industry:
Internist
Phone:
(718) 430-2908 (Phone)
Luciano Valdalbero-Luciano Rossetti
Professional information
Dr. Luciano Rossetti, Bronx NY - MD (Doctor of Medicine)
Specialties:
Internal Medicine
Address:
1300 Morris Park Ave, Bronx 10461
(718) 430-2908 (Phone)
(718) 430-2908 (Phone)
Languages:
English
Modulation Of Amino Acid Metabolism In The Hypothalamus
US Patent:
2010010, Apr 29, 2010
Filed:
Jun 21, 2006
Appl. No.:
11/921847
Inventors:
Luciano Rossetti - Bedford Hills NY, US
Tony Lam - Richmond Hill, CA
Tony Lam - Richmond Hill, CA
Assignee:
ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY - Bronx NY
SIGNUM PHARMACEUTICALS, INC. - Raleigh NC
SIGNUM PHARMACEUTICALS, INC. - Raleigh NC
International Classification:
A61K 31/401, A61K 31/195, A61K 38/44, A61K 38/45, A61P 3/00
US Classification:
424 944, 514423, 514561, 424 945
Abstract:
Methods for reducing peripheral blood glucose levels, food intake, glucose production, gluconeogenesis, triglyceride levels, and low density lipoprotein (VLDL) levels in mammals are provided. Also provided are methods of increasing glucose production and food intake in mammals. Further provided are methods of treating a disorder selected from the group consisting of obesity, type 2 diabetes, type 1 diabetes, hyperglycemia, insulin resistance, glucose intolerance, leptin resistance, metabolic syndrome, heart failure, ischemia, coronary heart disease, familial lipoprotein lipase deficiency, hypopituitarism, hyperlipidemia, hypertriglyceridemia, hyperVLDLemia, atherosclerosis, hypercholesterolemia, hypertension, and any combination of the foregoing. The methods involve manipulations of amino acid presence or metabolism in the hypothalamus of the mammal.
Intranasal Administration Of Modulators Of Hypothalamic Atp-Sensitive Potassium Channels
US Patent:
2007002, Feb 1, 2007
Filed:
Feb 13, 2006
Appl. No.:
11/353594
Inventors:
Louis Herlands - Cambridge MA, US
Luciano Rossetti - Bedford Hills NY, US
Alessandro Pocai - New York NY, US
Luciano Rossetti - Bedford Hills NY, US
Alessandro Pocai - New York NY, US
International Classification:
A61K 31/549, A61K 31/513, A61K 9/14
US Classification:
424489000, 514223200, 514269000
Abstract:
Provided are methods of increasing Kchannel activity in the hypothalamus of a mammal, methods of reducing glucose production in a mammal, methods of reducing peripheral glucose levels in a mammal, methods of reducing triglyceride levels in a mammal, methods of reducing very low density lipoprotein (VLDL) levels in a mammal, methods of methods of reducing gluconeogenesis in the liver of a mammal, methods of treating metabolic disorders such as diabetes, hyperglycemia, insulin resistance, glucose intolerance, metabolic syndrome and/or obesity, and methods of increasing glucose production and peripheral glucose levels in a mammal. Also provided are methods of treating heart failure, ischemia, coronary heart disease, familial lipoprotein lipase deficiency, hypopituitarism, hyperlipidemia, hypertriglyceridemia, hyperVLDLemia, atherosclerosis, hypercholesterolemia, hypertension, polycystic ovary syndrome, gonadotropin deficiency and/or amenorrhea.
Mammalian Hypothalamic Nutrient Modulation Of Glucose Metabolism
US Patent:
2011020, Aug 25, 2011
Filed:
Feb 14, 2011
Appl. No.:
13/026851
Inventors:
Luciano Rossetti - Bedford Hills NY, US
Tony Lam - Richmond Hill, CA
Tony Lam - Richmond Hill, CA
International Classification:
A61K 31/715, A61K 31/19, A61K 31/191, A61K 31/7004, A61P 3/10, A61P 3/00, A61P 1/14
US Classification:
514 53, 514557, 514 23, 514 54
Abstract:
Provided are methods of reducing glucose production in a mammal, methods of reducing food intake in a mammal, methods of inhibiting gluconeogenesis in the liver of a mammal, methods of reducing peripheral blood glucose levels in a mammal, methods of decreasing serum triglyceride levels in a mammal, and methods of decreasing very low density lipoprotein (VLDL) levels in a mammal.
Modulation Of Hypothalamic Atp-Sensitive Potassium Channels
US Patent:
2009001, Jan 8, 2009
Filed:
Feb 13, 2006
Appl. No.:
11/884298
Inventors:
Luciano Rossetti - Bedford Hills NY, US
Alessandro Pocai - Westfield NJ, US
Alessandro Pocai - Westfield NJ, US
International Classification:
A61K 31/549, A61P 3/08, A61P 3/10
US Classification:
5142232
Abstract:
Provided are methods of increasing Kactivity in the hypothalamus of a mammal, methods of reducing glucose production and peripheral blood glucose levels in a mammal, methods of inhibiting gluconeogenesis in the liver of a mammal, and methods of increasing glucose production and peripheral blood glucose levels in a mammal.
Regulation Of Food Intake And Glucose Production By Modulation Of Long-Chain Fatty Acyl-Coa Levels In The Hypothalamus
US Patent:
2007009, Apr 26, 2007
Filed:
Feb 12, 2004
Appl. No.:
10/545056
Inventors:
Luciano Rossetti - Bedford Hills NY, US
Silvana Obici - Bronx NY, US
Silvana Obici - Bronx NY, US
International Classification:
A61K 48/00, A61K 39/395
US Classification:
514044000, 424146100
Abstract:
Methods of reducing food intake and glucose production in a mammal, or restoring hepatic autoregulation are provided. The methods involve increasing long-chain fatty acyl-Co-A (LC-CoA) levels in the hypothalamus, or stimulating efferent fibers in the hepatic branch of the vagus nerve. Also provided are methods of increasing food intake and glucose production in a mammal. The methods involve decreasing long-chain fatty acyl-Co-A (LC-CoA) levels in the hypothalamus of the mammal.